Evaluation of the IND One Step Strep A Rapid Test vs. Culture

NCT ID: NCT01491776

Last Updated: 2012-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

315 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the ability of the IND One Step Strep A test to accurately test a throat swab specimen from a symptomatic patient for the presence or absence of Group A Streptococcus (Strep A) when compared to culture.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Group A Streptococcus is a principal cause of respiratory infections such as tonsillitis, pharyngitis, and scarlet fever. Since pharyngitis can lead to rheumatic fever or acute glomerulonephritis, it is important to differentiate streptococcal pharyngitis from viral disease during early stages of infection. The Strep A Rapid Test is a simple and rapid test which can detect Group A Streptococcal antigen directly from throat swabs allowing physicians to make a rapid diagnosis and to administer therapy immediately. The IND Diagnostic Inc. Strep A Rapid Test is a lateral flow immunoassay utilizing colloidal gold reagents labeled with Strep A antibody. The test detects either viable or nonviable organisms directly from throat swabs within 10 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Strep Throat

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female subjects three (3) years of age or older
* Patients exhibiting at least 3 of the following symptoms:

* fever
* sore throat
* swollen lymph nodes in the neck
* redness of the throat and tonsils
* white or yellow patches on the tonsils
* Must be able to collect 2 throat swab samples from patient

Exclusion Criteria

* Patients currently undergoing antibiotic treatment will be excluded from study
Minimum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IND Diagnostic Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Darin M. Gregory, MD

Role: PRINCIPAL_INVESTIGATOR

Pioneer Clinical Research

Sadia Dar, MD

Role: PRINCIPAL_INVESTIGATOR

HCCA Clinical Research

Sreedhar (Steve) Samudrala, MD

Role: PRINCIPAL_INVESTIGATOR

HCCA Clinical Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pioneer Clinical Research, LLC

Bellevue, Nebraska, United States

Site Status RECRUITING

HCCA Clinical Research

Franklin, Tennessee, United States

Site Status RECRUITING

HCCA Clinical Research

Smyrna, Tennessee, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andrea Goolsby, LPN-C, CCRC

Role: primary

402-291-8704

Amie Demming

Role: primary

615-627-1018

Amie Demming

Role: primary

615-627-1018

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IND-CSP-2011-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.